Placebo for Maridebart cafraglutide, AMG 133, AMG 133, AMG 133, AMG 133
20230227
Phase 3 small_molecule active
Quick answer
Placebo for Maridebart cafraglutide, AMG 133, AMG 133, AMG 133, AMG 133 for Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity is a Phase 3 program (small_molecule) at Amgen Technology (Ireland) UC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Amgen Technology (Ireland) UC
- Indication
- Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active